High Risk Characteristics for Clinical Failure After Isolated Femoropopliteal Peripheral Vascular Interventions

Abstract

Studies suggesting increased late mortality with paclitaxel-coated devices (PCDs) in femoropopliteal peripheral vascular interventions (PVIs) prompted the U.S. Food and Drug Administration to recommend limiting the use of PCDs to “patients at particularly high-risk for restenosis.” We aimed to characterize patients at high risk of restenosis and develop a risk score to guide clinicians in selecting patients for treatment with PCDs.